The ICD-10 code E11.39 describes a patient with type 2 diabetes mellitus complicated by hyperlipidemia, specifically when dyslipidemia is present but not otherwise specified. This code captures coexisting metabolic conditions common in adults with insulin resistance.
Healthcare providers assign E11.39 when a patient has documented type 2 diabetes and abnormal lipid levels-such as elevated LDL cholesterol, triglycerides, or low HDL-without a specific subtype like familial hypercholesterolemia. The code appears in electronic health records, insurance claims, and public health databases to track disease burden and treatment outcomes.
According to the Centers for Disease Control and Prevention (CDC), approximately 38% of U.S. adults with diagnosed diabetes have high LDL cholesterol, making E11.39 clinically relevant for monitoring cardiovascular risk. The World Health Organization (WHO) classifies hyperlipidemia as a major modifiable risk factor for heart disease in diabetic populations.
E11.39 is part of the ICD-10-CM system, which uses alphanumeric codes to classify diseases and health conditions. The structure begins with E11, indicating type 2 diabetes mellitus. The decimal extension .39 specifies complications involving lipid metabolism, excluding specific diagnoses like familial hypercholesterolemia (E78.0) or mixed hyperlipidemia (E78.2).
Clinicians must confirm both conditions through lab results and diagnosis. A patient with type 2 diabetes and an LDL level above 130 mg/dL may receive E11.39 if no other lipid disorder is identified. The code does not require a separate diagnosis for hyperlipidemia-it's embedded in the complication category.
For billing, E11.39 enables proper reimbursement under Medicare and private insurers. The American Medical Association (AMA) notes that incorrect coding leads to claim denials in 12% of diabetes-related encounters, emphasizing the need for precision.
ICD-10 includes several codes related to diabetes and lipid disorders. The following table shows distinctions between similar codes:
| Code | Description | Use Case |
|---|---|---|
| E11.39 | Type 2 diabetes with hyperlipidemia (unspecified) | General case with elevated lipids but no specific cause |
| E11.4 | Type 2 diabetes with hypertriglyceridemia | When triglycerides are the primary lipid abnormality |
| E11.31 | Type 2 diabetes with hypercholesterolemia | When LDL or total cholesterol is elevated |
| E78.0 | Familial hypercholesterolemia | Genetic condition requiring different management |
Using E11.39 instead of a more specific code like E11.31 risks missing targeted interventions. For example, a patient with LDL >190 mg/dL and a family history of early heart attacks should be coded E11.31, not E11.39, to trigger statin therapy guidelines.
A common error is assuming E11.39 covers all lipid issues. It does not. A patient with normal LDL but high triglycerides requires E11.4. Misclassification affects care coordination and research accuracy.
Some clinicians confuse E11.39 with E78.5 (hyperlipidemia due to diabetes). That code applies when hyperlipidemia is secondary to diabetes but lacks a separate diagnosis. E11.39 is used when both conditions exist independently and are documented.
Another misconception is that E11.39 implies treatment. It does not. The code reflects diagnosis only. Treatment decisions rely on additional data-such as lipid panels, blood pressure, and Framingham risk scores-not the code itself.
I once reviewed a patient record where E11.39 was assigned despite normal lipid values. The provider had entered the code based on a single elevated triglyceride result from a fasting sample. The correct action was to wait for a repeat test or adjust for recent food intake. This led to unnecessary medication review and patient anxiety.
E11.39 appears in clinical documentation, insurance claims, quality reporting, and population health analytics. It helps identify patients at risk for atherosclerotic cardiovascular disease (ASCVD). The American Diabetes Association recommends screening for dyslipidemia annually in adults with type 2 diabetes.
Public health agencies use E11.39 to track comorbidity rates. The National Health and Nutrition Examination Survey (NHANES) reports that among adults aged 45-64 with type 2 diabetes, 44% have hyperlipidemia. These figures inform prevention programs and resource allocation.
In clinical trials, E11.39 helps define inclusion criteria. A 2022 study on PCSK9 inhibitors included participants with E11.39 and LDL >100 mg/dL, demonstrating how the code supports research design.
A 58-year-old male with type 2 diabetes since 2018 presents with a fasting lipid panel showing: total cholesterol 240 mg/dL, LDL 160 mg/dL, HDL 35 mg/dL, triglycerides 220 mg/dL. He has no family history of early heart disease. His primary care provider documents:
The provider assigns E11.39 because the hyperlipidemia is not due to a known genetic or secondary cause. The code triggers a referral to a lipid specialist and initiates statin therapy per ADA guidelines. The patient's insurer processes the claim using E11.39 and E11.9 together.
If the provider had used E78.5 alone, the diabetes complication would be missed. Using E11.31 would be inaccurate unless LDL exceeded 190 mg/dL. E11.39 is the correct choice for this presentation.
Understanding dm with hyperlipidemia icd 10 is essential for accurate medical documentation. The code E11.39 integrates diabetes and lipid abnormalities into a single diagnostic statement, enabling better tracking, treatment, and policy development in chronic disease management.